BioGend Therapeutics

BioGend Therapeutics Co.,Ltd.

BioGend Therapeutics, a regenerative engineering company, focuses on the development of advanced biologic products for bone and joint repair and restoration.

Latest News

01 February

News Releases

“RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.

“RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF” Patent related to our products associated with Osteoinductive factor (OIF) was granted from USPTO.

19 January

News Releases

The Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fracture was conditional approved by US FDA

The Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fracture was conditional approved by US FDA

06 January

News Releases

Biogend acquired self-paid price for RevoCart one-step autologous cartilage repair system.

Biogend acquired self-paid price for RevoCart one-step autologous cartilage repair system.

22 December

News Releases

BioGend submitted the Investigational Device Exemption (IDE) of BiG001 with an indication of bone graft for treatment of open tibial fractures, a feasibility study, to USFDA.

16 December

News Releases

BioGend Therapeutics Co., Ltd. (stock code: 6733) held a performance presentation before stock listing on December 22, 2020

27 April

News Releases

BiG-009 “RevoCart One-step Autologous Cartilage Repair System” has received the premarket approval letter(Certificate No. 006689) from the TFDA.

21 April

News Releases

BioGend received the approval of antibiotics, Minocycline.

05 February

News Releases

Osteopharma (the licensor of the OIF in Japan) enrolled first patient for a nonunion clinical trial on Feb. 5, 2020.

Osteopharma (the licensor of the OIF in Japan) enrolled first patient for a nonunion clinical trial on Feb. 5, 2020.

02 December

News Releases

BioGend BiG-009 RevoCart Clinical Evaluation Report was accepted by the FDA

Products and Projects

Innovative Clinical Treatments

Particulate Autologous Cartialge Implantatiion (PACI)

No need for in-vitro cell culture

One-Step arthroscopic surgery

Fast and safe

Biologic Bone Graft

Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures. The biological mechanism involved in bone grafting include osteoconduction, osteoinduction, and osteogenesis.

4F, No. 3, Park Street, Nangang District, Taipei 115

info@biogend.com.tw

+886-2-2655-8366 Customer Service Telephone Number:0911-886-733

© 2019 BioGend Therapeutics Co.,Ltd. All rights reserved. 網頁設計 - 好點子數位創意